CCR2 and neoplasm: Although combining vaccine and CCR2/5i + αPD-1 in the presence of RT did not result in a synergistic survival effect or decrease in tumor growth rate, PDACs that are primed by other mechanisms (e.g., a non–T cell-inflamed mechanism) might still benefit from combination treatment with vaccine and CCR2/5i + αPD-1.